Renal cell carcinoma is the most common type of kidney cancer in adults. In recent decades, innovative surgical and systemic strategies have led to a considerable progress in the management of renal cell carcinoma. This article describes the recent strategies to overcome therapeutic resistance in renal carcinoma patients. Renal cell cancer (RCC) is a highly prevalent and lethal disease. The standard treatment and care include nephrectomy with close postoperative monitoring.
Although most patients are cured of RCC, recurrence rates range from 30% to 60% with metastasis of the disease that is rarely curable and typically lethal. Cytotoxic chemotherapy and radiation treatment alone are incapable of controlling the disease. Therefore, recent clinical studies focus on developing cytokine therapies, targeting angiogenesis and mTOR signaling. However, the patient response rate remains low as…
